title: Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death?
authors.forename: Derek V
authors.initials: DV
authors.lastname: Exner
authors.forename: George J
authors.initials: GJ
authors.lastname: Klein
mesh_terms: D000638:Amiodarone / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D002598:Chagas Cardiomyopathy / Q000453:epidemiology* / Q000628:therapy*; D016757:Death, Sudden, Cardiac / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D017147:Defibrillators, Implantable; D022062:Electrophysiologic Techniques, Cardiac; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013015:Sotalol / Q000627:therapeutic use*; D017180:Tachycardia, Ventricular / Q000453:epidemiology* / Q000628:therapy*; D018487:Ventricular Dysfunction, Left / Q000453:epidemiology / Q000628:therapy
chemical_list: D000889:Anti-Arrhythmia Agents; D013015:Sotalol; D000638:Amiodarone